DARUKA MAHADEVAN, MD, PHD
Osteopathic Medicine at Campbell Ave, Tucson, AZ
License number
Arizona 30621
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
1515 N Campbell Ave, Tucson, AZ 85724
Phone
(520) 626-2816
(520) 626-3754 (Fax)
(520) 874-7400
(520) 874-3425 (Fax)
(520) 626-3754 (Fax)
(520) 874-7400
(520) 874-3425 (Fax)
Personal information
See more information about DARUKA MAHADEVAN at radaris.comName
Address
Phone
1777 Orange Grove Rd, Tucson, AZ 85704
4132 Calle Marfil, Tucson, AZ 85712
Organization information
See more information about DARUKA MAHADEVAN at bizstanding.comDaruka Mahadevan MD,PHD
3838 N Campbell Ave, Tucson, AZ 85719
Industry:
Internist
Phone:
(520) 694-2873 (Phone)
Daruka Mahadevan
Professional information
See more information about DARUKA MAHADEVAN at trustoria.com
Dr. Daruka Mahadevan, Tucson AZ - MD (Doctor of Medicine)
Dr. Daruka Mahadevan, Tucson AZ - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Arizona Cancer Center at UMC North
3838 N Campbell Ave, Tucson 85719
(520) 694-2873 (Phone), (520) 626-2225 (Fax)
3838 N Campbell Ave, Tucson 85719
(520) 694-2873 (Phone), (520) 626-2225 (Fax)
Certifications:
Internal Medicine, 1998, Medical Oncology, 2003
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Arizona Cancer Center at UMC North
3838 N Campbell Ave, Tucson 85719
The University of Arizona Medical Center
1501 North Campbell Ave, Tucson 85724
The University of Arizona Medical Center - South
2800 East Ajo Way, Tucson 85713
3838 N Campbell Ave, Tucson 85719
The University of Arizona Medical Center
1501 North Campbell Ave, Tucson 85724
The University of Arizona Medical Center - South
2800 East Ajo Way, Tucson 85713
Education:
Medical School
University Of London, Kings College School Of Medical & Dental
Graduated: 1990
University Conn
Graduated: 1995
University Of Connecticut Health Sciences Center
Graduated: 1997
University Of Arizona Cancer Center
Graduated: 2002
University Of London, Kings College School Of Medical & Dental
Graduated: 1990
University Conn
Graduated: 1995
University Of Connecticut Health Sciences Center
Graduated: 1997
University Of Arizona Cancer Center
Graduated: 2002
Associate Professor Of Medicine At The University Of Arizona
Associate Professor Of Medicine At The University Of Arizona
Position:
Associate Professor of Medicine at The University of Arizona
Location:
Tucson, Arizona Area
Industry:
Higher Education
Work:
The University of Arizona
-
Associate Professor of Medicine
Daruka Mahadevan, Tucson AZ
Daruka Mahadevan, Tucson AZ
Specialties:
Hematologist
Address:
1515 N Campbell Ave, Tucson, AZ 85724
3838 N Campbell Ave, Tucson, AZ 85719
100 N Humphreys Blvd, Memphis, TN 38120
3838 N Campbell Ave, Tucson, AZ 85719
100 N Humphreys Blvd, Memphis, TN 38120
Education:
King's College London School of Medicine - Bachelor of Medicine, Bachelor of Surgery
Doctor of Medicine
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Protein Kinase Inhibitors
Protein Kinase Inhibitors
US Patent:
2009009, Apr 16, 2009
Filed:
Apr 13, 2007
Appl. No.:
11/735344
Inventors:
Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Chandler AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Ruben M. Munoz - Chandler AZ, US
Steven L. Warner - Sandy UT, US
Kimiko Della Croce - Tucson AZ, US
Daniel D. Von Hoff - Scottsdale AZ, US
Cory L. Grand - Dublin CA, US
James Welsh - Oro Valley AZ, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Chandler AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Ruben M. Munoz - Chandler AZ, US
Steven L. Warner - Sandy UT, US
Kimiko Della Croce - Tucson AZ, US
Daniel D. Von Hoff - Scottsdale AZ, US
Cory L. Grand - Dublin CA, US
James Welsh - Oro Valley AZ, US
Assignee:
Arizona Board of Regents on Behalf of The University of Arizona - Tucson AZ
Montigen Pharmaceuticals, Inc. - Salt Lake City UT
Montigen Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31/5377, C07D 487/04, A61K 31/519
US Classification:
5142328, 544250, 51425216, 544115, 514267
Abstract:
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from:and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
Protein Kinase Inhibitors
Protein Kinase Inhibitors
US Patent:
2008005, Feb 28, 2008
Filed:
Mar 1, 2007
Appl. No.:
11/680921
Inventors:
Laurence Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Chandler AZ, US
David Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Ruben Munoz - Chandler AZ, US
Steven Warner - Mesa AZ, US
Kimiko Della Croce - Tucson AZ, US
Daniel Von Hoff - Scottsdale AZ, US
Cory Grand - Salt Lake City UT, US
James Welsh - Oro Valley AZ, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Chandler AZ, US
David Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Ruben Munoz - Chandler AZ, US
Steven Warner - Mesa AZ, US
Kimiko Della Croce - Tucson AZ, US
Daniel Von Hoff - Scottsdale AZ, US
Cory Grand - Salt Lake City UT, US
James Welsh - Oro Valley AZ, US
Assignee:
Arizona Board of Regents on Behalf of The University of Arizona - Tucson AZ
SuperGen,Inc - Dublin CA
SuperGen,Inc - Dublin CA
International Classification:
A61K 31/496, A61P 35/00, A61P 43/00, C07D 241/04, C07D 401/14, C07D 403/02, C07D 471/04
US Classification:
514252170, 514252120, 514252140, 514252160, 544250000, 544284000, 544295000, 544358000
Abstract:
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:
including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from:
and wherein R, R, R, X, Z, L, Cycl, Land Cyclare as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
Substituted Tricyclic Compounds As Protein Kinase Inhibitors
Substituted Tricyclic Compounds As Protein Kinase Inhibitors
US Patent:
7326712, Feb 5, 2008
Filed:
Oct 14, 2004
Appl. No.:
10/965313
Inventors:
Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Highland UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Steven L. Warner - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Highland UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Steven L. Warner - Tucson AZ, US
Assignee:
Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ
Supergen, Inc. - Dublin CA
Supergen, Inc. - Dublin CA
International Classification:
C07D 471/14, A61K 31/519, A61P 35/04, C07D 239/70, A61K 31/517
US Classification:
514267, 544250, 544283, 544284, 544293, 5142661, 5142662, 51426624
Abstract:
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:.
Protein Kinase Inhibitors
Protein Kinase Inhibitors
US Patent:
2009014, Jun 4, 2009
Filed:
Aug 20, 2007
Appl. No.:
11/841574
Inventors:
Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Chandler AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Ruben M. Munoz - Chandler AZ, US
Steven L. Warner - Mesa AZ, US
Kimiko Della Croce - Tucson AZ, US
Daniel D. Von Hoff - Scottsdale AZ, US
Cory L. Grand - Salt Lake City UT, US
James Welsh - Oro Valley AZ, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Chandler AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Ruben M. Munoz - Chandler AZ, US
Steven L. Warner - Mesa AZ, US
Kimiko Della Croce - Tucson AZ, US
Daniel D. Von Hoff - Scottsdale AZ, US
Cory L. Grand - Salt Lake City UT, US
James Welsh - Oro Valley AZ, US
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA - TUCSON AZ
SUPERGEN, INC. - DUBLIN CA
SUPERGEN, INC. - DUBLIN CA
International Classification:
A61K 31/496, C07D 487/04, C07D 495/14, C07D 491/048, A61P 35/04
US Classification:
51425216, 544250
Abstract:
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from:and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
Protein Kinase Inhibitors
Protein Kinase Inhibitors
US Patent:
2005027, Dec 15, 2005
Filed:
Mar 29, 2005
Appl. No.:
11/092168
Inventors:
Laurence Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Tucson AZ, US
David Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Ruben Munoz - Tucson AZ, US
Steven Warner - Tucson AZ, US
Kimiko Della Croce - Tucson AZ, US
Daniel Von Hoff - Scottsdale AZ, US
Cory Grand - Salt Lake City UT, US
Daruka Mahadevan - Tucson AZ, US
Haiyong Han - Tucson AZ, US
David Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Ruben Munoz - Tucson AZ, US
Steven Warner - Tucson AZ, US
Kimiko Della Croce - Tucson AZ, US
Daniel Von Hoff - Scottsdale AZ, US
Cory Grand - Salt Lake City UT, US
Assignee:
Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ
Montigen Pharmaceuticals, Inc. - Salt Lake City UT
Montigen Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K031/519, C07D487/02
US Classification:
514267000, 544250000
Abstract:
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:
including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from:
and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
Substituted Tricyclic Compounds As Protein Kinase Inhibitors
Substituted Tricyclic Compounds As Protein Kinase Inhibitors
US Patent:
8552018, Oct 8, 2013
Filed:
Mar 18, 2011
Appl. No.:
13/051790
Inventors:
Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Steven L. Warner - Sandy UT, US
James Welsh - Oro Valley AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Sridevi Bashyam - Bangalore, IN
Steven L. Warner - Sandy UT, US
James Welsh - Oro Valley AZ, US
Assignee:
Arizona Board of Regents on behalf of the University of Arizona - Tucson AZ
Astex Pharmaceutials, Inc. - Dublin CA
Astex Pharmaceutials, Inc. - Dublin CA
International Classification:
A61K 31/519, A61K 31/496, A61P 35/04, C07D 491/14, C07D 471/14, C07D 239/70, A61K 31/517
US Classification:
514267, 544250, 544283, 544284, 544293, 5142661, 5142662, 51426624
Abstract:
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:.
Composition And Method For Cancer Treatment
Composition And Method For Cancer Treatment
US Patent:
2012003, Feb 16, 2012
Filed:
Jun 2, 2011
Appl. No.:
13/151635
Inventors:
Daruka MAHADEVAN - Tucson AZ, US
Assignee:
University of Arizona - Tucson AZ
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241351, 4241381, 4241331
Abstract:
Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.